Three insights that will change how you approach integrated delivery networks

25 January 2017

Healthcare reform and financial pressures are leading to increased integration within siloed organizations across healthcare systems. Integrated delivery networks (IDNs) are growing in importance for pharmaceutical manufacturers as they now represent the majority of the healthcare spend in the USA, writes Theresa Greco, vice president, life sciences, health care, LexisNexis Risk Solutions, in a weekly expert view piece.

Consider this: In the USA, there are 1,500 IDNs with over 67,000 parent/child relationships; 250 group purchasing organizations (GPOs) with more than 94,000 purchasing relationships and 800 accountable care organizations (ACOs) with more than 4,000 relationships to health care and IDNs.1

Business considerations become as important as clinical ones

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK